EUR 73.8
(0.27%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 529.27 Million EUR | -1.94% |
2022 | 539.77 Million EUR | 3.55% |
2021 | 521.27 Million EUR | 21.94% |
2020 | 427.46 Million EUR | 7.95% |
2019 | 395.99 Million EUR | 7.62% |
2018 | 367.94 Million EUR | 4.48% |
2017 | 352.17 Million EUR | 0.52% |
2016 | 350.35 Million EUR | 2.26% |
2015 | 342.61 Million EUR | 8.66% |
2014 | 315.29 Million EUR | 5.2% |
2013 | 299.72 Million EUR | 0.48% |
2012 | 298.29 Million EUR | 4.98% |
2011 | 284.13 Million EUR | 0.74% |
2010 | 282.04 Million EUR | 9.72% |
2009 | 257.05 Million EUR | 9.67% |
2008 | 234.39 Million EUR | 0.44% |
2007 | 233.36 Million EUR | 10.29% |
2006 | 211.59 Million EUR | 7.62% |
2005 | 196.61 Million EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 264.44 Million EUR | 0.0% |
2023 Q2 | 256.24 Million EUR | 0.0% |
2023 Q4 | 273.02 Million EUR | 0.0% |
2023 FY | 529.29 Million EUR | -1.94% |
2022 Q4 | 269.01 Million EUR | 0.0% |
2022 FY | 539.77 Million EUR | 3.55% |
2022 Q2 | 270.76 Million EUR | 0.0% |
2021 FY | 521.27 Million EUR | 21.94% |
2021 Q2 | 255.33 Million EUR | 0.0% |
2021 Q4 | 265.94 Million EUR | 0.0% |
2020 Q2 | 196.11 Million EUR | 0.0% |
2020 Q4 | 231.35 Million EUR | 0.0% |
2020 FY | 427.46 Million EUR | 7.95% |
2019 Q2 | 183.78 Million EUR | 0.0% |
2019 FY | 395.99 Million EUR | 7.62% |
2019 Q4 | 212.2 Million EUR | 0.0% |
2018 Q2 | 177.86 Million EUR | 0.0% |
2018 FY | 367.94 Million EUR | 4.48% |
2018 Q4 | 190.07 Million EUR | 0.0% |
2017 Q4 | 174.49 Million EUR | 0.0% |
2017 Q2 | 177.68 Million EUR | 0.0% |
2017 FY | 352.17 Million EUR | 0.52% |
2016 Q4 | 178.1 Million EUR | 0.0% |
2016 Q2 | 172.24 Million EUR | 0.0% |
2016 FY | 350.35 Million EUR | 2.26% |
2015 FY | 342.61 Million EUR | 8.66% |
2015 Q4 | 175.44 Million EUR | 0.0% |
2015 Q2 | 167.16 Million EUR | 0.0% |
2014 Q4 | 165.9 Million EUR | 0.0% |
2014 Q2 | 149.39 Million EUR | 0.0% |
2014 FY | 315.29 Million EUR | 5.2% |
2013 FY | 299.72 Million EUR | 0.48% |
2013 Q2 | 145.5 Million EUR | 0.0% |
2013 Q4 | 154.22 Million EUR | 0.0% |
2012 FY | 298.29 Million EUR | 4.98% |
2012 Q2 | 74.57 Million EUR | 0.0% |
2012 Q4 | 74.93 Million EUR | 0.48% |
2012 Q3 | 74.57 Million EUR | 0.0% |
2012 Q1 | 74.57 Million EUR | 0.0% |
2011 Q2 | 71.03 Million EUR | 0.0% |
2011 Q1 | 71.03 Million EUR | 0.0% |
2011 Q3 | 71.03 Million EUR | 0.0% |
2011 Q4 | 74.57 Million EUR | 4.98% |
2011 FY | 284.13 Million EUR | 0.74% |
2010 Q2 | 70.51 Million EUR | 0.0% |
2010 Q3 | 70.51 Million EUR | 0.0% |
2010 Q4 | 71.03 Million EUR | 0.74% |
2010 FY | 282.04 Million EUR | 9.72% |
2010 Q1 | 70.51 Million EUR | 0.0% |
2009 FY | 257.05 Million EUR | 9.67% |
2009 Q1 | 64.26 Million EUR | 0.0% |
2009 Q4 | 70.51 Million EUR | 9.72% |
2009 Q3 | 64.26 Million EUR | 0.0% |
2009 Q2 | 64.26 Million EUR | 0.0% |
2008 Q1 | 58.59 Million EUR | 0.0% |
2008 FY | 234.39 Million EUR | 0.44% |
2008 Q4 | 64.26 Million EUR | 9.67% |
2008 Q3 | 58.59 Million EUR | 0.0% |
2008 Q2 | 58.59 Million EUR | 0.0% |
2007 Q2 | 58.34 Million EUR | 0.0% |
2007 Q1 | 58.34 Million EUR | 0.0% |
2007 FY | 233.36 Million EUR | 10.29% |
2007 Q4 | 58.59 Million EUR | 0.44% |
2007 Q3 | 58.34 Million EUR | 0.0% |
2006 Q2 | 52.89 Million EUR | 0.0% |
2006 FY | 211.59 Million EUR | 7.62% |
2006 Q1 | 52.89 Million EUR | 0.0% |
2006 Q3 | 52.89 Million EUR | 0.0% |
2006 Q4 | 58.34 Million EUR | 10.29% |
2005 Q4 | 52.89 Million EUR | 7.62% |
2005 FY | 196.61 Million EUR | 0.0% |
2005 Q1 | 49.15 Million EUR | 0.0% |
2005 Q2 | 49.15 Million EUR | 0.0% |
2005 Q3 | 49.15 Million EUR | 0.0% |
2004 Q4 | 49.15 Million EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Boiron SA | 493.24 Million EUR | -7.303% |
Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 36.195% |
Valneva SE | 153.71 Million EUR | -244.326% |
AB Science S.A. | 970 Thousand EUR | -54464.021% |
Nanobiotix S.A. | 30.05 Million EUR | -1660.832% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -39814.857% |
Vivoryon Therapeutics N.V. | -3.62 Million EUR | 14720.746% |
BioSenic S.A. | 543 Thousand EUR | -97371.639% |
ABIVAX Société Anonyme | 4.62 Million EUR | -11353.603% |
Formycon AG | 77.69 Million EUR | -581.208% |